

March 16, 2015



## **Actinium to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference March 20th in New York City**

NEW YORK, NY -- (Marketwired) -- 03/16/15 -- [Actinium Pharmaceuticals, Inc.](http://www.actiniumpharma.com) (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 22<sup>nd</sup> Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 11:00 a.m. The conference will take place at the Millennium Broadway Hotel and Conference Center in New York City.

Kaushik J. Dave, President and CEO, will provide an overview of the company and recent activities. You can view the presentation webcast at <http://www.actiniumpharma.com/investors/events/>.

Future Leaders connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment and partnering opportunities and the chance to find companies with tier-jumping potential.

Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or [esmith@actiniumpharma.com](mailto:esmith@actiniumpharma.com).

### ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical lomab<sup>TM</sup>-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab<sup>TM</sup>-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

### ***Forward-Looking Statement for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities

Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc. Evan Smith, CFA VP Investor Relations and Finance (646)  
esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals